Update in Cutaneous Lupus Treatment and Collaborative Care Considerations for the Systemic Lupus Patient

The presentation provides an update on treatments for cutaneous lupus and highlights the importance of collaborative care between dermatologists and rheumatologists for patients with systemic lupus erythematosus (SLE). The speaker, a dermatologist-rheumatologist from UT Southwestern, outlines current and emerging treatment paradigms, stating that antimalarials remain the backbone of therapy for localized disease, while more refractory cases may require second and third-line therapies. Recent advancements include the introduction of targeted biologics and a focus on clinical trial designs to enhance drug development for cutaneous lupus. Notable emerging therapies include anifrolumab, lefilumab, and ducravacitinib, all showing promise in upcoming trials. The necessity for effective communication between dermatologists and rheumatologists is emphasized, particularly in monitoring symptoms and selecting appropriate therapies that consider both skin and systemic involvement. The presentation underscores the need for ongoing data collection through clinical trials to improve treatment outcomes for this patient population.